Abarelix cas 183552-38-7

Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.

Properties:

Density: 1.286g/cm3

Boiling Point: 1688.4ºC at 760mmHg

Flash Point: 974.9ºC

Refractive Index: 1.601

Vapor Pressure: 0mmHg at 25°C

Related Products:

Plecanatide; Linaclotide; Carbetocin; Octreotide acetate; Terlipressin; Cetrorelix; Desmopressin; Desmopressin acetate; Degarelix; Goserelin acetate; Ganirelix Acetate; GLP-1 (7-37); Semaglutide

[1]. Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7.

[2]. Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4.